Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services
14 Aprile 2014 - 2:00PM
Marketwired
Medicure Engages Knight Therapeutics Inc. to Provide Advisory
Services
WINNIPEG, MANITOBA--(Marketwired - Apr 14, 2014) - Medicure Inc.
("Medicure" or the "Company") (TSX-VENTURE:MPH)(OTCQB:MCUJF), a
specialty pharmaceutical company, today announced it has entered
into an arrangement with Knight Therapeutics Inc.
(TSX-VENTURE:GUD), under which Knight will provide advisory
services to help advance Medicure's U.S. specialty pharmaceutical
business and corporate development initiatives.
"Medicure is pleased to have the opportunity to work with
Jonathan Ross Goodman, co-founder of Paladin Labs Inc. and CEO of
Knight Therapeutics Inc." stated Dr. Albert D. Friesen, CEO and
Chair of Medicure Inc. "We look forward to benefitting from the
depth of experience and networks that he has built up in
establishing and growing a successful specialty pharmaceutical
business."
Jonathan Ross Goodman, CEO of Knight Therapeutics Inc.
commented, "I am pleased to leverage my skills and experience to
help Medicure further grow its business."
About Knight Therapeutics
Knight Therapeutics Inc., headquartered in Montreal, Canada, is
a specialty pharmaceutical company focused on acquiring or
in-licensing innovative pharmaceutical products for the Canadian
and world markets. Knight Therapeutics' shares began trading on the
TSX-V on March 3, 2014 under the symbol GUD. For more information
about Knight Therapeutics, please visit the company's web site at
www.gud-knight.com or at www.sedar.com
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the
development and commercialization of novel small molecule
therapeutics. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban HCl) for
non-ST elevation acute coronary syndrome in the United States,
where it is sold through the Company's U.S. subsidiary, Medicure
Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.com/newsreleases.html
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release. Forward Looking Information Statements contained in
this press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, including the potential
for Medicure to attain material benefit from the advisory services
of Knight Therapeutics, are based on the current assumptions,
estimates, analysis and opinions of management of the Company made
in light of its experience and its perception of trends, current
conditions and expected developments, as well as other factors
which the Company believes to be relevant and reasonable in the
circumstances. Inherent in forward-looking statements are known and
unknown risks, uncertainties and other factors beyond the Company's
ability to predict or control that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements, and as such, readers are cautioned not
to place undue reliance on forward-looking statements.
Such risk factors include, among others, the Company's future
product revenues, stage of development, additional capital
requirements, risks associated with the completion and timing of
clinical trials and obtaining regulatory approval to market the
Company's products, the ability to protect its intellectual
property, dependence upon collaborative partners, changes in
government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on
a number of assumptions which may prove to be incorrect, including,
but not limited to, assumptions about: general business and
economic conditions; the impact of changes in Canadian-US dollar
and other foreign exchange rates on the Company's revenues, costs
and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of
current and future clinical trials; the uncertainties associated
with the acceptance and demand for new products and market
competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended May 31, 2013.
Medicure Inc.Dawson ReimerPresident &
COO888-435-2220204-488-9823info@medicure.comwww.medicure.com
Grafico Azioni Medicure (PK) (USOTC:MCUJF)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Medicure (PK) (USOTC:MCUJF)
Storico
Da Dic 2023 a Dic 2024
